ArticleClinical and experimental medicine2025
Development and external validation of a predictive model for lung metastases in kidney cancer based on clinical and laboratory features.
Article in Clinical and experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A novel prognostic nomogram for elderly renal cell carcinoma patients with lung metastases.Scientific reports · 2026Article
- A robust privacy-preserving federated framework for kidney CT image classification using transfer learning models.Frontiers in artificial intelligence · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundLung metastases (LMs) are common and clinically significant in kidney cancer, contributing to poor prognosis and limited treatment response. Early detection of patients at high risk for LMs is crucial for developing personalized treatment strategies.
methodsThis retrospective study included 2652 patients with kidney cancer, pathologically confirmed, from two medical centers between 2000 and 2020. A training cohort (n = 1500) was used to develop a predictive model for LMs based on clinical, pathological, and laboratory variables. Multivariate logistic regression was applied to identify independent predictors, and a nomogram was constructed. Model performance was evaluated using receiver operating characteristic (ROC) curves, calibration plots, probability density functions (PDFs), and decision curve analysis (DCA). An external validation cohort (n = 1152) was used to assess generalizability.
resultsFamily cancer history, advanced T stage, and N nodal stage were identified as independent predictors of LMs. The nomogram demonstrated excellent discrimination in the training cohort (AUC = 0.938) and moderate performance in the validation cohort (AUC = 0.883), outperforming individual variables. Calibration analysis showed good agreement between predicted and observed probabilities. Patients with LMs had significantly worse overall survival than those without (p < 0.001). DCA validated the nomogram's greater clinical value over treat-all or treat-none approaches.
conclusionThis nomogram-based model offers an efficient and accessible tool for the early detection of kidney cancer patients at risk for LMs. It enables individualized risk stratification and may assist in optimizing clinical decision-making and improving patient outcomes. Further prospective validation is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.